Palbociclib exposure in relation to efficacy and toxicity in patients with advanced breast cancer

Authors: Buijs, S.M. ^{1, ∗}, Mohmaed Ali, M.I. ², Oomen-de Hoop, E. ¹, Braal, C.L. ¹, Wortelboer, N. ¹, van Ommen-Nijhof, A. ³, Sonke, G.S. ³, Konings, I.R. ⁴, Jager, A. ¹, Steeghs, N. ^{3, 5}, Siebinga, H. ², Mathijssen, R.H.J. ¹, Huitema, A.D.R. ^{2, 6, 7}, Koolen, S.L.W. ^{1, 8}

Source: In ESMO Open March 2025 10(3)

An ultra-sensitive liquid chromatography tandem mass spectrometry method for the simultaneous quantification of 2H6-alectinib and alectinib in human plasma to support a microtracer food-effect trial

Authors: van der Heijden, L.T. ^{a, b, ⁎}, Tibben, M.M. ^a, Mohmaed Ali, M.I. ^a, Aardenburg, L.G.J. ^a, Steeghs, N. ^{c, d}, Beijnen, J.H. ^{a, e}, Rosing, H. ^a, Huitema, A.D.R. ^{a, f, g}

Source: In Journal of Chromatography B 1 March 2025 1253

Factors for a broad technology assessment of comprehensive genomic profiling in advanced cancer, a systematic review

Authors: van Schaik, L.F., Engelhardt, E.G., Wilthagen, E.A., Steeghs, N., Fernández Coves, A., Joore, M.A., van Harten, W.H., Retèl, V.P.

Source: In Critical Reviews in Oncology / Hematology October 2024 202

Interleukin-6 in relation to early recurrence in primary, localized soft tissue sarcoma: An addition for existing risk classification systems?

Authors: van der Laan, P. ^{a, b}, van der Graaf, W.T.A. ^{b, c}, van den Broek, D. ^d, van Boven, H. ^e, Heeres, B.C. ^f, Schrage, Y. ^a, Haas, R.L. ^{g, h}, Steeghs, N. ^b, van Houdt, W.J. ^{a, ∗}

Source: In European Journal of Surgical Oncology September 2024 50(9)

Health-related quality of life in patients with gastrointestinal stromal tumor: data from a real-world cohort compared with a normative population

Authors: van de Wal, D., den Hollander, D., Desar, I.M.E., Gelderblom, H., Oosten, A.W., Reyners, A.K.L., Steeghs, N., van der Graaf, W.T.A., Husson, O.

Source: In ESMO Real World Data and Digital Oncology June 2024 4

Sunitinib for the treatment of metastatic gastrointestinal stromal tumors: the effect of TDM-guided dose optimization on clinical outcomes

Authors: Giraud, E.L., Westerdijk, K., van der Kleij, M.B.A., Guchelaar, N.A.D., Meertens, M., Bleckman, R.F., Rieborn, A., Mohammadi, M., Roets, E., Mathijssen, R.H.J., Huitema, A.D.R., Koolen, S.L.W., Gelderblom, H., Moes, D.J.A.R., Reyners, A.K.L., Touw, D.J., Keizer-Heldens, P., Oosten, A.W., van der Graaf, W.T.A., Steeghs, N., van Erp, N.P., Desar, I.M.E.

Source: In ESMO Open June 2024 9(6)

Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022

Authors: Araujo, D., Greystoke, A., Bates, S., Bayle, A., Calvo, E., Castelo-Branco, L., de Bono, J., Drilon, A., Garralda, E., Ivy, P., Kholmanskikh, O., Melero, I., Pentheroudakis, G., Petrie, J., Plummer, R., Ponce, S., Postel-Vinay, S., Siu, L., Spreafico, A., Stathis, A., Steeghs, N., Yap, C., Yap, T.A., Ratain, M., Seymour, L.

Source: In Annals of Oncology January 2023 34(1):48-60

Sex differences in patients with gastrointestinal stromal tumours: do they exist and does it affect survival?

Authors: IJzerman, N.S., van Werkhoven, E., Mohammadi, M., Hollander, D. den, Bleckman, R.F., Reyners, A.K.L., Desar, I.M.E., Gelderblom, H., Grünhagen, D.J., Mathijssen, R.H.J., Steeghs, N., van der Graaf, W.T.A.

Source: In ESMO Open December 2022 7(6)

Complete genomic characterization in patients with cancer of unknown primary origin in routine diagnostics

Authors: Schipper, L.J., Samsom, K.G., Snaebjornsson, P., Battaglia, T., Bosch, L.J.W., Lalezari, F., Priestley, P., Shale, C., van den Broek, A.J., Jacobs, N., Roepman, P., van der Hoeven, J.J.M., Steeghs, N., Vollebergh, M.A., Marchetti, S., Cuppen, E., Meijer, G.A., Voest, E.E., Monkhorst, K.

Source: In ESMO Open December 2022 7(6)

Therapeutic drug monitoring-based precision dosing of oral targeted therapies in oncology: a prospective multicenter study

Authors: Groenland, S.L., van Eerden, R.A.G., Westerdijk, K., Meertens, M., Koolen, S.L.W., Moes, D.J.A.R., de Vries, N., Rosing, H., Otten, H., Vulink, A.J.E., Desar, I.M.E., Imholz, A.L.T., Gelderblom, H., van Erp, N.P., Beijnen, J.H., Mathijssen, R.H.J., Huitema, A.D.R., Steeghs, N.

Source: In Annals of Oncology October 2022 33(10):1071-1082

Double burden: financial toxicity in patients with advanced soft tissue sarcoma at the start of first-line palliative chemotherapy: baseline data from the HOLISTIC study.

Authors: Roets, E., Younger, E., Jones, R. L., Hollander, D.den, Desar, I. M. E., Young, R. J., Oosten, A. W., de Haan, J. J., Gelderblom, H., Steeghs, N., van der Graaf, W. T. A., Husson, O.

Source: Supportive Care in Cancer; Mar2025, Vol. 33 Issue 3, p1-11, 11p

Quality of life with encorafenib plus cetuximab with or without binimetinib treatment in patients with BRAF V600E-mutant metastatic colorectal cancer: patient-reported outcomes from BEACON CRC

Authors: Kopetz, S., Grothey, A., Van Cutsem, E., Yaeger, R., Wasan, H., Yoshino, T., Desai, J., Ciardiello, F., Loupakis, F., Hong, Y.S., Steeghs, N., Guren, T.K., Arkenau, H.-T., Garcia-Alfonso, P., Belani, A., Zhang, X., Tabernero, J.

Source: In ESMO Open June 2022 7(3)

The use of microtracers in food‐effect trials: An alternative study design for toxic drugs with long half‐lives exemplified by the case for alectinib.

Authors: van der Heijden, L. T.^1,2 (AUTHOR) l.vd.heijden@nki.nl, Steeghs, N.³ (AUTHOR), Beijnen, J. H.^1,2,4 (AUTHOR), Huitema, A. D. R.^1,2,5,6 (AUTHOR), Dorlo, T. P. C.^1,2,7 (AUTHOR)

Source: CTS: Clinical & Translational Science. Dec2023, Vol. 16 Issue 12, p2557-2564. 8p.

Subject Terms: *DRUG design, *EXPERIMENTAL design, *ANTINEOPLASTIC agents, *CONFIDENCE intervals, *BLOOD sampling

Priorities and preferences of advanced soft tissue sarcoma patients starting palliative chemotherapy: baseline results from the HOLISTIC study

Authors: Younger, E., Jones, R.L., den Hollander, D., Soomers, V.L.M.N., Desar, I.M.E., Benson, C., Young, R.J., Oosten, A.W., de Haan, J.J., Miah, A., Zaidi, S., Gelderblom, H., Steeghs, N., Husson, O., van der Graaf, W.T.A.

Source: In ESMO Open October 2021 6(5)

Safety of tarlatamab with 6-8-h outpatient versus 48-h inpatient monitoring during cycle 1: DeLLphi-300 phase 1 substudy

Authors: Chiang, A.C. ^{1, ∗}, Olmedo Garcia, M.E. ², Carlisle, J.W. ³, Dowlati, A. ^{4, 5}, Reguart, N. ⁶, Felip, E. ^{7, 8}, Jost, P.J. ⁹, Steeghs, N. ¹⁰, Stec, R. ^{11, 12}, Gadgeel, S.M. ¹³, Loong, H.H. ^{14, 15}, Jiang, W. ¹⁶, Hamidi, A. ¹⁶, Parkes, A. ¹⁶, Paz-Ares, L. ^{17, 18, 19, 20}

Source: In ESMO Open April 2025 10(4)

Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors

Authors: Heinhuis, K.M., Ros, W., Kok, M., Steeghs, N., Beijnen, J.H., Schellens, J.H.M. ^*

Source: In Annals of Oncology February 2019 30(2):219-235

Validation and clinical application of an LC-MS/MS method for the quantification of everolimus using volumetric absorptive microsampling

Authors: Verheijen, R.B., Thijssen, B., Atrafi, F., Schellens, J.H.M., Rosing, H., de Vries, N., Beijnen, J.H., Mathijssen, R.H.J., Steeghs, N., Huitema, A.D.R.

Source: In Journal of Chromatography B 1 January 2019 1104:234-239

Molecular Tumor Boards: current practice and future needs

Authors: van der Velden, D.L., van Herpen, C.M.L., van Laarhoven, H.W.M., Smit, E.F., Groen, H.J.M., Willems, S.M., Nederlof, P.M., Langenberg, M.H.G., Cuppen, E., Sleijfer, S., Steeghs, N., Voest, E.E. ^*

Source: In Annals of Oncology December 2017 28(12):3070-3075

Setting the international research agenda for sarcomas with patients and carers: results of phase II of the Sarcoma Patient Advocacy Global Network (SPAGN) priority setting partnership.

Authors: Roets, E., Schuster, K., Bickley, S., Wartenberg, M., Gonzato, O., Fernandez, N., Kasper, B., Pilgermann, K., Wilson, R., Steeghs, N., van der Graaf, W. T. A., van Oortmerssen, G., Husson, O.

Source: BMC Cancer; 8/6/2024, Vol. 24 Issue 1, p1-10, 10p

Subject Terms: PATIENT advocacy, OSTEOSARCOMA, SARCOMA, GASTROINTESTINAL stromal tumors, PATIENT participation

The time to progression ratio: a new individualized volumetric parameter for the early detection of clinical benefit of targeted therapies

Authors: Cirkel, G.A., Weeber, F., Bins, S., Gadellaa-van Hooijdonk, C.G.M., van Werkhoven, E., Willems, S.M., van Stralen, M., Veldhuis, W.B., Ubink, I., Steeghs, N., de Jonge, M.J., Langenberg, M.H.G., Schellens, J.H.M., Sleijfer, S., Lolkema, M.P., Voest, E.E. ^*

Source: In Annals of Oncology August 2016 27(8):1638-1643